Prescient is an evidence-based decision-support partner to the pharmaceutical and biotech industries whose mission is to optimally shape new product, brand and mature product planning strategies.

Our diverse yet integrated skillsets and methodologies ensure our clients’ key decisions are objectively assessed from both a clinical and commercial perspective, resulting in differentiated products and offerings.


Shaping Decisions Driving Value

Our People

Prescient’s team consists of highly experienced executives who share our core values of thinking collaboratively, creatively and constructively. We effectively integrate different skills and perspectives into a single client-engagement team.

Our Approach

The format and scope of our engagements are customized to meet our clients’ needs and our ‘best-in-front’ team philosophy ensures access to the necessary levels of expertise and thinking.

Our Clients

We engage directly with a number of functions supporting new product, brand and mature product planning activities; to view a full list of these, please click the
link below.

Latest News

IBM and Pfizer to accelerate immuno-oncology research with Watson for Drug Discovery

Study suggests possible new target for treating and preventing Alzheimer's

Takeda to invest more than 100 million Euros in dengue vaccine manufacturing plant in Germany

Stop smoking! Quitting at any age reduces the risk of death after 70

Boehringer Ingelheim and China Southeast University collaborate to develop new treatment approaches …

AstraZeneca takes latest scientific advances in oncology to major US And European congresses

Smart patch releases blood thinners as needed

GSK Announces EU Regulatory Submission of Candidate Vaccine for Prevention of Shingles

Among antidementia drugs, memantine is associated with the highest risk of pneumonia

Benzodiazepine and related drug use increases hip fractures in persons with Alzheimer's disease

World of viruses uncovered

Lilly announces top-line results of solanezumab phase 3 clinical trial

Shire to establish rare disease innovation hub in Cambridge, Mass.

Greater efforts are needed to encourage patients to report adverse drug reactions

Sex, gender, or both in medical research

Boehringer axes small-molecule discovery ops as R&D focus shifts to immuno-oncology

Chutes & Ladders: Pfizer’s longtime official Maddaluna retires as EVP

Takeda and Lightstone join forces to fund and launch neuroscience upstart

Intellia gears up for human testing of CRISPR with new HQ, set to double staffers

Amryt secures €20M to fund pivotal rare disease trial

Will he stay or will he go? Crunch time approaches for FDA's Califf

Sean Parker’s I/O group teams up with CRI for cancer neoantigens R&D deal

House passes 21st Century Cures Act, authorizing $4.8B in NIH funding and causing concern about FDA …

AstraZeneca inks big, backloaded deal for bicyclic peptides

After Juno deaths, Bluebird posts positive CAR-T safety, efficacy signals

Early data on OncoMed's cancer antibodies 'intriguing, but preliminary'

Microbiome CNS upstart launches with $19.15M Series A

Arrowhead snaps after trial hold as it targets major layoffs, ditches programs

Heptares to buy G7 to bolster GPCR capabilities

Sanofi takes over Warp Drive antibiotic program

A look back at pharma news to Dec 2

Avastin biosimilar filed with EMA

Positive new trial data for Xultophy

bluebird bio flying high on CAR-T results

Japanese approval for GSK’s COPD drug; EU filling

Pulmaquin failure halves Aradigm's value

Meeting highlights from the Pharmacovigilance Risk Assessment

China-developed product could become first long-acting anti-HIV drug worldwide

Diabetes drugs could have Alzheimer’s impact, analysis says

New Australian legislation will improve access to medicines and cut red-tape

Lyrica meets primary endpoint in Phase III pediatric epilepsy trial

Warning that direct-acting antivirals, used for hepatitis C, may reactivate hepatitis B

With a robust economy, Israeli pharma market set to reach $2.12 billion by 2020

Announcement hails breakthrough in sequencing technology

NICE now recommends Merck’s new lung cancer drug

Medical News Today: Erythroblastosis Fetalis: Causes, Symptoms, and Treatment

Medical News Today: Can Tea Tree Oil Help Treat Psoriasis?

Medical News Today: Why you should never go to sleep on an argument

Medical News Today: Vegetarian diets best for health and the environment, say nutritionists

Medical News Today: Can Coconut Oil Help Treat Psoriasis?

Medical News Today: White wine may raise melanoma risk

Medical News Today: Bipolar Psychosis: Symptoms, Treatment, and Outlook

Medical News Today: Community groups keep us mentally sharp as we age

Medical News Today: Drinking plenty of fluids when ill may do more harm than good

Medical News Today: Gut microbiome contributes to Parkinson's, study suggests

Medical News Today: Bone loss may be linked to Alzheimer's disease

Medical News Today: Natural Remedies for Treating Bipolar Disorder

Medical News Today: What Is My Life Expectancy If I Have Lupus?

Medical News Today: Complex regional pain syndrome: Watching others causes pain

Medical News Today: Diabetes breakthrough: Insulin-producing cells formed using malaria drugs

Clinical researchers in the Americas – could you win a coveted Pharma?

AZ, Bicycle pair up to develop bicyclic peptides

MSD drops price of Keytruda for NICE nod

Pfizer employs artificial intelligence for drug discovery

GPs should test for HIV in routine appointments

Cancer research gets £226 million investment

Conditional EU nod for Takeda’s Ninlaro

NICE backs GSK’s novel asthma biologic

AbbVie’s risankizumab bags Orphan status for paediatric Crohn’s

Hunt announces £1m pilot scheme to retain GPs over 55

MedImmune, Abpro create new firm

US speedy review for Merck, Pfizer’s avelumab

UK biotechs link in gene therapy deal

NICE backs anastrozole for breast cancer prevention

Merck files Keytruda for MSI-H cancer

More News